Inclusion Criteria:  Patient is ≥18 years of age Established and well documented ITP diagnosis Patient is treated with, or at enrollment prescribed, Doptelet for ITP. Decision to initiate treatment shall be made by the treating physician and independently from the decision to include the patient in the study Signed and dated informed consent provided by the patient before any study-related activities are undertaken Willing and able to comply with protocol requirements  Exclusion Criteria:  Enrollment in another concurrent clinical interventional study, or intake of an Investigational Medicinal Product (IMP), within three months prior to inclusion in this study ITP secondary to Evan's syndrome, lupus and other autoimmune diseases ITP secondary to other hematological disorders and hematological malignancies ITP secondary to any other malignancies ITP secondary to known drug toxicity ITP secondary to any other disease considered relevant by the Investigator